Clinical Trials
RPA Haematology has been highly active in clinical trials over many years, and is one of the highest recruiters of many Australian and multi-national clinical trials in Haematology.
RPA Haematology has been highly active in clinical trials over many years, and is one of the highest recruiters of many Australian and multi-national clinical trials in Haematology. Our clinical trial activity covers a wide portfolio – myeloma in all stages of disease, acute myeloid and lymphoblastic leukaemia, acute promyelocytic leukaemia, numerous subtypes of lymphoma (eg. diffuse large B cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and primary CNS lymphoma), chronic lymphocytic leukaemia, myelofibrosis, myelodysplasia, allogeneic stem cell transplantation, haemophilia, haemoglobinopathies and iron overload.
We a maintain a strong commitment to collaborative group trials carried out under the auspices of organisations such as the Australasian Leukaemia and Lymphoma Group (ALLG), of which the RPA Haematology team are key members, European Myeloma Network (EMN) and other organisations. We actively partner with Pharmaceutical companies to provide our patients with the opportunity to access new therapeutic options and to advance therapies in a wide range of malignant and non-malignant haematological conditions.. Our unit is considered a leading site for investigative studies and members of our staff often lead Investigator driven national trials. Some actively recruiting trials are investigating
Myeloma
We are participating in a new trial using a new antibody-combination drug in combination with other medicines used for patients who have relapsed or have refractory multiple myeloma. The antibody part of the drug identifies and binds to the multiple myeloma cancer cells then the medication part of the drug kills the targeted cells.
Myeloma and Lymphoma
RPAH Haematology is a major Australian site conducting multinational trials on Chimeric Antigen Receptor (CAR)-T cells. These trials bring these ground-breaking therapies to Australian patients, withRPA as site for ongoing CAR-T cell clinical trials in NSW and Australia.
Leukaemia
We are participating in a ALLG-initiated trial in patients with recently diagnosed acute lymphoblastic leukaemia (ALL). This trial will see if using a new drug in place of a standard chemotherapy component (from the existing ALL treatment program) leads to lower amounts of minimal residual disease (in the bone marrow). In addition, a trial in recently diagnosed patients with Acute Myeloid Leukaemia (AML) specifically targeting patients who have the FLT3 gene mutation is also enrolling, testing state of the art drug targeting the mutationIn the last 3 years we have carried out 28 clinical trials,, screened 450 and enrolled 216 patients, including the opening of 16 trials in one year. In 2020, we have 41 on-going clinical trials (of which 14 are currently enrolling patients in Myeloma, Acute Leukaemia, Lymphoma and Haemophilia) and expect to offer 15 new trials (later in 2020 and early 2021) to patients at RPAH.
A list of available trials may be found via the ClinTrialRefer app which is available for free download through the iTunes and Google Playstore. Any inquiry about our trials may be directed to Dr Christine Contacos, RPA Haematology Clinical trials manager.